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Abstract
Background: Acne vulgaris (acne) is a common skin condition in children and ado-
lescents. Efficacy of tretinoin is well documented in studies that included pediatric
patients (12‐18 years of age). With acne routinely presenting in younger patients,
data are needed in this important group. Lotion formulations are commonly used
across dermatology and are well liked by patients.
Objective: To evaluate the safety and efficacy of a novel once‐daily tretinoin 0.05%
lotion in preadolescent subjects (≤ 13 years) with moderate‐to‐severe acne.
Methods: Post hoc analysis of two multicenter, randomized, double‐blind, vehicle‐
controlled phase 3 studies in moderate-to-severe acne. Preadolescent subjects
(N = 154) randomized (1:1) to receive tretinoin 0.05% lotion or vehicle, once daily
for 12 weeks. Efficacy assessments included changes in baseline inflammatory/non-
inflammatory lesions and treatment success (at least 2‐grade reduction in Evaluator's
Global Severity Score [EGSS] and clear/almost clear). Safety, adverse events (AEs),
and cutaneous tolerability evaluated throughout.
Results: At Week 12, mean percent reduction in inflammatory and noninflammatory
lesion counts were 49.5% and 44.0% compared with 31.4% and 18.8% with vehicle
(both P = 0.001). Treatment success was achieved by 23.7% of subjects by Week
12, compared with 7.2% (P = 0.009). The majority of AEs were mild and transient:
most frequently were application site pain (5.6%) and application site dryness (2.8%).
Local cutaneous safety and tolerability assessments were generally mild‐to‐moderate
and improved by Week 12.
Conclusions: Tretinoin 0.05% lotion was significantly more effective than vehicle in
achieving treatment success and reducing inflammatory and noninflammatory lesions
in preadolescent acne. It was well tolerated, with all treatment‐related AEs deemed
mild or moderate.
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1 | INTRODUCTION
Preadolescent acne (≤ 13 years) is common and may be one of the
first signs of pubertal maturation. The trend to onset of adrenarche
and menarche at an earlier age mirrors the increasingly younger age
of acne onset. Comedones tend to predominate, but inflammatory
lesions can also be present. Preadolescent acne severity may also be
predictive of future disease severity, especially if it remains
untreated until the patient is older.1 Treatment of preadolescent
acne is therefore important not only to ameliorate the development
of more severe acne but also to reduce physical and emotional
impact and perhaps improve adherence in later life.
Data related to treatment of preadolescent acne are limited, with
most medications approved for age 12 and above; off‐label prescrib-
ing is common. Topical retinoids (eg, tretinoin, adapalene) have
played an essential role in acne management because they inhibit
the development of microcomedones and new acne papules.2,3
However, there is a common perception that they are primarily
effective in comedonal acne,4 and their use is associated with signifi-
cant cutaneous irritation.5,6
A new lotion formulation of tretinoin 0.05% has recently been
developed leveraging polymerized emulsion technology with the aim
to improve both efficacy and tolerability of tretinoin. Here, a post
hoc analysis of two large phase 3 clinical studies (N = 1640) evalu-
ates its safety and efficacy in a preadolescent acne population with
moderate‐to‐severe acne.
2 | METHODS
2.1 | Study design
This was a post hoc analysis of two identical multicenter, random-
ized, double‐blind, vehicle‐controlled, parallel group clinical studies in
pediatric subjects with moderate‐to‐severe acne. Protocols received
approval before patient enrollment from the appropriate institutional
review board (IRB) and were conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practices (GCP) and in compli-
ance with local regulatory requirements. All subjects were informed
of the study details and provided written consent.
2.2 | Study population
Eligible subjects included male and female patients of any race and
ethnicity aged 9‐13 years who presented with 20‐40 inflammatory
lesions (papules, pustules, and nodules), 20‐100 noninflammatory
lesions (open and closed comedones), and two nodules or less. A
washout period of 2‐4 weeks was required for subjects who used
previous prescription and over‐the‐counter acne treatments.
Subjects were enrolled with an Evaluator Global Severity Score
(EGSS) of 3 (moderate) or 4 (severe); randomized (1:1) to tretinoin
0.05% lotion or matched vehicle lotion applied once daily for
12 weeks. They were instructed to gently wash their faces with
approved cleanser and warm water, rinsing thoroughly and gently
patting their face dry. During the study, each subject was permit-
ted to use only approved nonmedicated cleansers, moisturizers,
and sunscreens. Lists of approved cleanser and moisturizers were
provided. Subjects applied a pea‐sized amount of study drug, dot-
ted on six facial areas, and gently rubbed into the skin covering
the entire face (excluding mouth, eyes, inside nose, and lips).
Study drug was applied the same time of day, once daily for
12 weeks.
2.3 | Efficacy evaluation
Efficacy evaluations comprised inflammatory and noninflammatory
lesion counts and an EGSS assessment at screening, baseline, and
subsequent study visits (Weeks 4, 8, and 12). Efficacy end points
included mean percent change from baseline to Week 12 in inflam-
matory and noninflammatory lesion counts and the proportion of
subjects achieving at least a 2‐grade reduction from baseline EGSS
and “clear” or “almost clear” at that same visit.
Additional assessments included a patient satisfaction score (PSS)
and a validated acne‐specific quality of life (Acne‐QoL) questionnaire
(Merck & Co., Inc. Whitehouse, NJ). At baseline, subjects were asked
to rate their satisfaction with prior acne therapy with a PSS of 1‐10
(where 10 was the most satisfied and a score of 5 or greater was
considered as “satisfied”). At Week 12, they were asked to rate their
level of satisfaction with study treatment. Subjects assessed facial
shine/oiliness at baseline and Week 12 using a 4‐point scale, and
those recording a score of 1‐3 were asked to rate degree of bother-
someness (using a 5‐point scale).
2.4 | Safety evaluation
Cutaneous safety (erythema and scaling) and tolerability (itching,
burning, and stinging) were evaluated on a scale from 0 (none) to 3
(severe). Adverse events (AEs) were evaluated throughout; severity
and relationship with study medication were assessed.
2.5 | Statistical analysis
The intent‐to‐treat (ITT) population comprised all subjects random-
ized and provided with study drug and vehicle. The safety population
comprised all randomized subjects who were presumed to have used
the study medication or vehicle at least once and who provided at
least one postbaseline evaluation. The primary method of handling
missing efficacy data in the ITT analysis set was based on estimation
using the Markov chain Monte Carlo multiple imputation methods.
No imputations were made for missing safety data.
Treatment comparisons of percent reductions in lesions counts
utilized a ranked analysis of covariance with factor of treatment and
the respective baseline lesion count as covariate. Significance of
EGSS reductions was obtained from logistic regression (using Firth's
Penalized Likelihood) with factors of treatment group. There was no
imputation of missing data for quality of life analyses. Mean Acne-




covariance with factors of treatment and the respective baseline
lesion count as covariate. Shininess/oiliness and PSS scores were
compared between treatment groups using a Wilcoxon Rank Sum
test. All statistical analyses were conducted using SAS® version 9.3
or later. Statistical significance was based on 2‐tailed tests of the null
hypothesis resulting in P values of 0.05 or less.
All AEs occurring during the studies were recorded and classi-
fied on the basis of medical dictionary for drug regulatory activi-
ties terminology (MedDRA) for the safety population. Treatment
emergent adverse events (TEAEs), defined as any AE with an
onset on or after the date of first drug application, were summa-
rized by treatment group and relationship with study drug. Each
subject was counted only once within a system organ class or a
preferred term using the event with the greatest severity or
causality, respectively.
3 | RESULTS
3.1 | Baseline characteristics
One hundred fifty-four subjects were included in the post hoc analy-
sis. Of those, 139 (90.3%) completed the studies, including 64 pread-
olescent subjects (86.5%) on tretinoin 0.05% lotion and 75 (93.8%)
on vehicle (Figure 1). The most common reasons for study discontin-
uation were “lost to follow‐up” or “subject request.”
Demographic data (Table 1) were similar across the treatment
groups. Mean age (standard deviation [SD]) was 12.4 (0.94) years.
Subjects were predominantly White (74.7%) and women (59.1%).
There were no noticeable differences between treatment groups
with regard to lesion counts or EGSS. At baseline, the mean number
(SD) of inflammatory and noninflammatory lesions was 26.7 (6.04)
and 50.3 (21.90); 94.2% of subjects had moderate acne (EGSS = 3).
F IGURE 1 Patient disposition showing percent completion and
reasons for discontinuation (ITT pediatric population pooled data)
TABLE 1 Demographics and baseline characteristics (ITT pediatric population, pooled data)
Study 301 + 302 (pooled data pediatric population)
Tretinoin 0.05%, (N = 74) Vehicle, (N = 80) Total, (N = 154)
Age—Mean years (SD) 12.4 (0.97) 12.4 (0.92) 12.4 (0.94)
Range 9‐13 9‐13 9‐13
Sex N (%)
Male 31 (41.9%) 32 (40.0%) 63 (40.9%)
Female 43 (58.1%) 48 (60.0%) 91 (59.1%)
Ethnicity N (%)
Hispanic or latino 17 (23.0%) 24 (30.0%) 41 (26.6%)
Not hispanic or latino 57 (77.0%) 56 (70.0%) 113 (73.4%)
Race N (%)
American Indian or Alaska Native 0 (0.0%) 0 (0.0%) 0 (0.0%)
Asian 3 (4.1%) 2 (2.5%) 5 (3.2%)
Black or African‐American 14 (18.9%) 15 (18.8%) 29 (18.8%)
Native Hawaiian or Other Pacific Islander 0 (0.0%) 2 (2.5%) 2 (1.3%)
White 55 (74.3%) 60 (75.0%) 115 (74.7%)
Other 2 (2.7%) 1 (1.3%) 3 (1.9%)
Evaluator's global severity score N (%)
3—Moderate 72 (97.3%) 73 (91.3%) 145 (94.2%)
4—Severe 2 (2.7%) 7 (8.8%) 9 (5.8%)
inflammatory lesion count—Mean (SD) 26.2 (5.50) 27.2 (6.49) 26.7 (6.04)
Noninflammatory lesion count—Mean (SD) 48.3 (22.01) 52.1 (21.78) 50.3 (21.90)




3.2.1 | Lesion counts
Tretinoin 0.05% lotion resulted in statistically significant reductions
in inflammatory and noninflammatory lesion counts compared to
vehicle from Week 8 through Week 12. Notably, there was no addi-
tional improvement seen with vehicle beyond the reduction in non-
inflammatory lesion counts reported at Week 8. Mean percentage
change (LS mean) from baseline to Week 12 in inflammatory and
noninflammatory lesion counts was 49.5% and 44.0% compared with
31.4% and 18.8% with vehicle (both P = 0.001); see Figures 2 and 3.
3.2.2 | Treatment success
By Week 12, 23.7% of subjects were treatment successes (at least a
2‐grade improvement in global severity by EGSS and “clear” or “al-
most clear”) following treatment with tretinoin 0.05% lotion com-
pared to only 7.2% on vehicle (P = 0.009); see Figure 4.
3.2.3 | Patient satisfaction and quality of life
Subject satisfaction with treatment was significantly greater with tre-
tinoin 0.05% lotion than vehicle by Week 12 (P = 0.008). Although
there were no statistically significant differences in the improvement
F IGURE 2 Percent change in
inflammatory lesions from baseline to
Week 12 (ITT pediatric population pooled
data, LS Mean)
F IGURE 3 Percent change in
noninflammatory lesions from baseline to
Week 12 (ITT population pooled data, LS
Mean)
F IGURE 4 Treatment success. Subjects
with at least a 2‐grade improvement and
“clear” or “almost clear” at each study visit




between treatment groups based on the mean Acne‐QoL assess-
ments in each of the four evaluated domains, the increases in mean
scores from baseline to Week 12 with tretinoin 0.05% lotion were
greater than vehicle for self‐perception (3.7 vs 3.5), role‐emotional
(3.4 vs 3.0), and acne symptoms (3.7 vs 3.0).
3.3 | Safety
A similar number of subjects in each treatment group (22 and 18,
tretinoin 0.05% lotion and vehicle, respectively) reported treatment
emergent (TE) AEs. All TEAEs experienced in the tretinoin 0.05%
lotion group were mild or moderate events (Table 2).
Treatment‐related AEs reported by ≥ 1% of subjects treated with
tretinoin 0.05% lotion were application site pain (5.6%); dryness
(2.8%); and irritation, exfoliation, or pruritus (each 1.4%).
3.4 | Cutaneous safety and tolerability
Erythema and scaling were recorded by the investigator. Overall
mild‐to‐moderate erythema was noted in 43% of subjects at base-
line, with 12% reporting mild‐to‐moderate scaling. Mean scores for
both erythema and scaling increased at Week 4 (to 0.6 and 0.5,
respectively, where 0 = mild) following treatment with tretinoin
0.05% lotion, returning to baseline levels by the end of the study
(Figure 5).
Levels of itching, burning, and stinging were obtained from the
subjects. Overall, 19% of subjects reported mild‐to‐moderate itching
at baseline. Only four subjects (6%) reported any itching by Week
12. Reports of burning (N = 7, 5%) and stinging (N = 6, 4%) were
infrequent and mild at baseline. Mean scores increased very slightly
at Week 4 (to 0.3 and 0.2, respectively, where 0 = mild) with treti-
noin 0.05% lotion, again returning to baseline levels by Week 12.
4 | DISCUSSION
Topical retinoids are routinely used to treat acne; safety and efficacy
are well documented in large pivotal trials. With limited FDA‐
approved treatment options for preadolescent acne, off‐label pre-
scribing is common. Monotherapy with adapalene gel, tretinoin gel,
and tretinoin microsphere gel has been investigated in small open‐
label and blinded studies in children under 12 years of age.7-9 How-
ever, data in preadolescent acne are lacking.
In a 12‐week open‐label study of 40 children (8‐12 years) with
mild‐to‐moderate acne, tretinoin microsphere 0.04% gel produced a
TABLE 2 Safety: Treatment emergent and related adverse event
(AE) characteristics through Week 12 (safety pediatric population,
pooled data)
Tretinoin
0.05% lotion Vehicle lotion
Subjects reporting any TEAE 22 (30.6%) 18 (23.1%)
Subjects reporting any SAE 0 (0.0%) 0 (0.0%)
Subjects who died 0 (0.0%) 0 (0.0%)
Subjects who discontinued
due to TEAE
1 (1.4%) 0 (0.0%)
Severity of AEs reported
Mild 11 (15.3%) 11 (14.1%)
Moderate 11 (15.3%) 4 (5.1%)
Severe 0 (0.0%) 3 (3.8%)
Relationship with study drug
Related 7 (9.7%) 1 (1.3%)
Unrelated 15 (20.8%) 17 (21.8%)
Treatment‐related AEs reported by ≥ 1% subjects
Application site pain 4 (5.6%) 0 (0.0%)
Application site dryness 2 (2.8%) 0 (0.0%)
Application site exfoliation 1 (1.4%) 1 (1.3%)
Application site pruritus 1 (1.4%) 0 (0.0%)
Application site irritation 1 (1.4%) 0 (0.0%)
F IGURE 5 Cutaneous safety and
tolerability assessment from baseline to
Week 12 (Safety pediatric population,
pooled data)
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significant decrease in EGSS from baseline to Week 12 (from 2.6 to
2.1, P < 0.0001). Eight patients (22.2%) were “clear” or “almost
clear.” Skin irritation occurred in 35% of patients, being generally
mild and transient.8 In a subsequent double‐blind study with treti-
noin microsphere 0.04% gel in 110 children (9‐11 years) with moder-
ate acne, there was a significantly greater improvement in
noninflammatory lesions (44.0% reduction) compared to vehicle
(30.8%, P = 0.04) at Week 12.9 In a post hoc analysis of two studies
comparing tretinoin microsphere 0.1% gel and tretinoin 0.05% gel in
young adolescents (10‐14 years) with mild‐to‐moderate acne, compa-
rable lesion reduction and treatment success were noted. Tretinoin
0.05% gel demonstrated better cutaneous tolerability.10 Fourteen
percent of participants reported dry skin, 8% skin burning sensation,
5% erythema, and 5% dermatitis exfoliative compared with 32%,
11%, 23%, and 23%, respectively, with tretinoin gel microsphere
0.1% (all P < 0.001, except skin burning sensation).
Tretinoin 0.05% lotion is a novel topical treatment for moderate‐
to‐severe acne leveraging polymerized emulsion technology. The
development rationale was to provide a tretinoin formulation with
improved efficacy and tolerability that could be especially suited to a
preadolescent population. The polymerized emulsion provides a
mesh (a polymeric network) which helps structure the emulsion pro-
viding uniform distribution of active and hydrating ingredients at the
surface of the skin, reducing the presence of concentrated drug in
specific areas (hot spots). It also forms a barrier which helps keep
the skin hydrated by reducing epidermal water loss and increasing
skin water content.
Tretinoin 0.05% lotion was shown to provide significantly greater
efficacy than vehicle in two pivotal phase 3 studies.11 Data reported
herein were consistent with these overall findings. Tretinoin 0.05%
lotion offered significantly more efficacy than vehicle in inflammatory
and noninflammatory lesion reduction and treatment success, with
greater patient satisfaction (compared with vehicle) and preference
(compared with previous acne therapy). Efficacy in comedonal acne
(44% mean reduction) was similar to that reported previously with tre-
tinoin microsphere 0.04% gel,9 although our analysis included preado-
lescent subjects with severe disease. To our knowledge, we are the
first to report efficacy in inflammatory lesions (50% mean reduction).
Results in this pediatric population were similar to those seen in the
overall study populations. The only difference of note is that the vehi-
cle tended to be less effective in the pediatric population.
In the overall study populations, tretinoin 0.05% lotion showed
significantly greater QoL benefits relative to vehicle. Although there
were numerical differences in our post hoc analysis, they were not
significant and may reflect the appropriateness of some of the indi-
vidual questions to a preadolescent acne population, given the rela-
tively low mean scores are baseline compared with the overall study
populations.
Tretinoin 0.05% lotion was generally safe and very well toler-
ated.11 The most commonly reported treatment‐related AEs included
application site reactions and skin‐related events attributed to the
known properties of tretinoin. There were slightly more treatment‐
related AEs when compared to the overall study populations.
Most noteworthy was the extremely low irritation potential of
this novel tretinoin formulation. The level of irritation seen with tre-
tinoin 0.05% lotion in our study appears lower than that reported in
clinical studies with tretinoin microsphere gel (0.04% or 0.1% con-
centrations) or tretinoin gel 0.05% in preadolescent acne;8-10 how-
ever, direct comparisons are difficult to make in the absence of
head‐to‐head trials.
5 | CONCLUSION
A novel tretinoin 0.05% lotion formulation was an effective and
well‐tolerated topical treatment for moderate‐to‐severe comedonal
and inflammatory preadolescent acne.
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